World Health Organization Sounds Warning Over Acute Lack of Weight-Loss Injections

Fewer than one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it releases its first advice on the medications.

Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just access to this class of drugs.

According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The new guidelines recognises that obesity is a chronic disease that can be treated with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are key barriers to widespread access to the jabs that can aid individuals in losing considerable body mass, explains the organization.

Skinny Jab Supply Crisis

Despite the present most optimistic case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The recommendation encourages countries and companies to increase access, via measures like patent sharing.

A patent on a key compound – the main ingredient of a leading brand – is set to lapse in a number of countries in 2026.

How Weight-Loss Drugs Operate

GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so users reduce food intake.

Individuals usually start to lose weight in the initial weeks of starting on the weekly injections.

Evidence points to users may see weight return after a year of discontinuing the medication, when their usual hunger come back.

Being above a healthy weight raises your likelihood for developing diseases, including diabetes, cardiovascular issues, stroke, and some cancers.

Excess weight impacts individuals in all nations and was associated with millions of fatalities worldwide in 2024, per the WHO.